Tag: allergic conjunctivitis
May 15, 2017
Aldeyra Therapeutics Shares Financials for Q1 2017
Aldeyra Therapeutics released their financial results for their first quarter of 2017 and provided a corporate update. April 18, 2017
Aldeyra Doses Last Patient in Allergic Conjunctivitis Trial
Aldeyra Therapeutics announced the last patient dosing for its Phase 2b clinical trial of ADX-102 in allergic conjunctivitis. March 14, 2017
Tetra Bio-Pharma Enters into Binding Term Sheet for Two Products with Panag Pharma
Tetra Bio-Pharma(CSE:TBP) has entered into a binding term sheet with Panag Pharma for the development and commercialization of novel cannabinoid... November 14, 2016
Ocular Therapeutix™ Announces Successful Topline Results from Phase 3 Clinical Trial of DEXTENZA™
Ocular Therapeutix today announced positive topline results from its phase 3 clinical trial of DEXTENZA™ (dexamethasone insert) 0.4 mg, for... November 14, 2016
Aldeyra Therapeutics Announces Third Quarter 2016 Financial Results
Aldeyra Therapeutics, a biotechnology company focused on the development of products to treat diseases related to aldehydes, today reported third... November 9, 2016
Ocular Therapeutix Reports Third Quarter 2016 Financial Results and Provides Corporate Update
Ocular Therapeutix, a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the... October 11, 2016
